ESMO Asia 2023 is on the horizon, and prominent pharmaceutical companies like Imunopharm Technology, Shanghai Henlius Biotech, and others are poised for the conference in order to present and discuss the most recent scientific and clinical achievements in oncology, both globally and in the Asia-Pacific region.

Myeloid and lymphatic tumors resulting from the disturbance of regular hematopoietic function are categorized as hematological malignancies. These malignancies typically include leukemia, multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). The content provides an overview of significant abstracts related to hematological malignancies scheduled for presentation at the forthcoming ESMO Asia 2023.

Hematological Malignancies Highlights

• Abstract Number – 328MO
• Abstract Type – Mini Oral Session 
• Indication – Relapsed or refractory B-cell Non-Hodgkin Lymphoma

 

Title: The pivotal clinical study of IM19 CAR-T cells in the treatment of relapsed or refractory aggressive B cell non-Hodgkin lymphomas

Executive Summary: IM19 treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma can achieve a high rate of durable responses, with an extremely low incidence of grade III or more severe Cytokine Release Syndrome (CRS) and neurotoxicity.

Main Content: IM19 is a CAR-T cell therapy that targets CD19 and is manufactured using the patient's own cells. Produced in China through a standardized process, the drug is currently undergoing assessment in a Phase Ib/II pivotal trial to evaluate its efficacy and safety in individuals with aggressive B-cell non-Hodgkin lymphomas that have relapsed or proven refractory.

As of the data cutoff on June 15, 2023, ninety-nine patients underwent leukapheresis for CAR-T cell production, and 71 received IM19 treatment. Among the 59 patients assessed for efficacy, the primary 3-month objective response rate (ORR) was 51%. Incidences of cytokine release syndrome (CRS) and neurotoxicity were 42% and 7%, respectively, with no severe cases reported. Additional information is expected to be disclosed during the forthcoming ESMO Asia 2023 conference.

 

List of Abstracts to be presented at ESMO Asia 2023